Omnicell Inc. ($0.001 par value) (OMCL) Peer Comparison
$36.41
$-0.24
(-0.65%)
As on 02-Nov-2026 16:00EST
Market cap
$1,667 Mln
Revenue (TTM)
$1,244 Mln
P/E Ratio
38.2
P/B Ratio
1.3
Div. Yield
0 %
Edit
| Omnicell Inc. ($0.001 par value) (OMCL) | Penumbra (PEN) | Avantor (AVTR) | Repligen (RGEN) | Glaukos Corp (GKOS) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
1,667 | 12,682 | 10,876 | 11,234 | 14,302 |
Revenue ($ Mln) |
1,244 | 1,560 | 6,636 | 806 | 690 |
Net Profit ($ Mln) |
44.67 | 157.02 | 337.20 | -11.80 | -169.80 |
Net Margin (%) |
3.59 | 10.06 | 5.08 | -1.47 | -24.60 |
RoE (%) |
3.47 | 10.27 | 5.90 | -0.56 | -24.46 |
Price to Earnings |
38.18 | 79.11 | 32.10 | -- | -- |
Price-To-Book |
1.27 | 8.19 | 1.94 | 5.37 | 20.01 |
Income Statement ($ Mln)
| Omnicell Inc. ($0.001 par value) (OMCL) | Penumbra (PEN) | Avantor (AVTR) | Repligen (RGEN) | Glaukos Corp (GKOS) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,243.92 | 1,560.33 | 6,635.60 | 805.61 | 690.33 |
|
Cost of Revenue
|
682.47 | 499.55 | 4,539.20 | 394.34 | 130.29 |
|
Gross Profit
|
508.04 | 942.44 | 2,139.40 | 347.62 | 393.22 |
|
Operating Expenses
|
495.80 | 871.54 | 1,593.70 | 392.34 | 623.34 |
|
Operating Profit (EBIT)
|
65.65 | 189.25 | 502.70 | 18.93 | -63.30 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
67.24 | 207.82 | 315.50 | 8.23 | -174.52 |
|
Provision for Tax
|
22.58 | 50.81 | -21.70 | 20.03 | -4.72 |
|
Profit after Tax (Net Income)
|
44.67 | 157.02 | 337.20 | -11.80 | -169.80 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 47.34 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Omnicell Inc. ($0.001 par value) (OMCL) | Penumbra (PEN) | Avantor (AVTR) | Repligen (RGEN) | Glaukos Corp (GKOS) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,317.26 | 1,583.51 | 5,835.90 | 2,091.74 | 717.27 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
265.88 | 207.78 | 4,425.10 | 708.99 | 135.53 |
|
Current Liabilities
|
473.70 | 233.81 | 1,369.00 | 125.69 | 126.73 |
|
Total Liabilities
|
1,974.72 | 1,826.52 | 11,794.70 | 2,949.70 | 893.49 |
Assets ($ Mln)
| Omnicell Inc. ($0.001 par value) (OMCL) | Penumbra (PEN) | Avantor (AVTR) | Repligen (RGEN) | Glaukos Corp (GKOS) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,272.86 | 648.47 | 9,037.40 | 1,684.42 | 399.88 |
|
Current Assets
|
783.98 | 1,376.63 | 2,592.60 | 1,241.98 | 579.65 |
|
Total Assets
|
1,974.72 | 1,826.52 | 11,794.70 | 2,949.70 | 893.49 |
|
Total Debt*
|
189.67 | 209.39 | 3,683.80 | 692.24 | 101.98 |
|
Net Current Assets
|
0.00 | 0.00 | 1,223.60 | 0.00 | 452.92 |
Cashflow ($ Mln)
| Omnicell Inc. ($0.001 par value) (OMCL) | Penumbra (PEN) | Avantor (AVTR) | Repligen (RGEN) | Glaukos Corp (GKOS) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
127.30 | 238.66 | 623.80 | 117.42 | -46.34 |
|
Cash Flow from Investing Activities
|
-60.36 | -404.59 | -130.50 | -298.47 | -77.61 |
|
Cash from Financing Activities
|
-218.32 | 26.53 | -409.40 | -15.21 | 11.89 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Omnicell Inc. ($0.001 par value) (OMCL) | Penumbra (PEN) | Avantor (AVTR) | Repligen (RGEN) | Glaukos Corp (GKOS) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
0.13 | 11.76 | -5.43 | 1.79 | -22.53 |
|
ROE (%)
|
3.47 | 10.27 | 5.90 | -0.56 | -24.46 |
|
ROA (%)
|
1.70 | 5.91 | 2.57 | -0.33 | -15.48 |
|
EBIT Margin (%)
|
5.53 | 13.40 | 7.39 | 4.20 | -24.51 |
|
Net Margin (%)
|
3.59 | 10.06 | 5.08 | -1.47 | -24.60 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Omnicell Inc. ($0.001 par value) (OMCL) | Penumbra (PEN) | Avantor (AVTR) | Repligen (RGEN) | Glaukos Corp (GKOS) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
5.62 | 16.98 | 0.92 | 13.80 | 46.94 |
|
EBIT Growth (%)
|
89.21 | 11.72 | 106.97 | 29.47 | -106.70 |
|
Net Profit Growth (%)
|
124.22 | -4.27 | 510.22 | -779.17 | -93.80 |
|
EPS Growth (%)
|
124.33 | -4.95 | 507.22 | -910.66 | -90.00 |
|
Book Value Growth (%)
|
6.58 | 15.61 | 4.89 | 0.35 | -12.58 |
Valuation Ratios
| Omnicell Inc. ($0.001 par value) (OMCL) | Penumbra (PEN) | Avantor (AVTR) | Repligen (RGEN) | Glaukos Corp (GKOS) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
992.52 | 68.93 | -14.68 | 189.42 | -34.59 |
|
Price / Book Value
|
1.65 | 8.58 | 1.40 | 4.40 | 9.90 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
19.93 | 53.25 | 81.94 | 50.32 | -43.50 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Omnicell Inc. ($0.001 par value) (OMCL) | Penumbra (PEN) | Avantor (AVTR) | Repligen (RGEN) | Glaukos Corp (GKOS) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.63 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | 0.01 | 0.01 | 0.01 | 0.00 |
|
Current Ratio
|
1.66 | 5.89 | 1.89 | 9.88 | 4.57 |
|
Quick Ratio
|
1.45 | 3.92 | 1.27 | 8.43 | 4.09 |
|
Interest Coverage
|
19.38 | 165.16 | 2.81 | 1.24 | -35.23 |
Operating Efficiency Ratios
| Omnicell Inc. ($0.001 par value) (OMCL) | Penumbra (PEN) | Avantor (AVTR) | Repligen (RGEN) | Glaukos Corp (GKOS) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
18.98 | 12.51 | 16.92 | 18.77 | 21.73 |
|
Asset Turnover
|
0.47 | 0.59 | 0.51 | 0.22 | 0.63 |
|
Receivable days
|
72.94 | 46.54 | 58.79 | 72.41 | 60.95 |
|
Inventory Days
|
51.15 | 331.92 | 64.13 | 146.53 | 193.84 |
|
Payable days
|
25.84 | 26.16 | 58.13 | 29.05 | 60.19 |
|
Cash Conversion Cycle
|
98.25 | 352.30 | 64.79 | 189.88 | 194.60 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
